Geneva, Oct. 9 -- International Clinical Trials Registry received information related to the study (NCT07855133) titled 'A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Semaglutide Medication' on Sept. 28.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Novo Nordisk A/S
Condition:
Overweight
Obesity
Type 2 Diabetes
Intervention:
Drug: Semaglutide
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: September 30, 2026
Target Sample Size: 60
Countries of...